Immatics N.V. (NASDAQ:IMTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $19.20.

Several equities research analysts have recently commented on the company. Mizuho set a $25.00 price target on Immatics in a research note on Thursday, February 19th. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Guggenheim raised their target price on shares of Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of Immatics in a research note on Monday, November 24th.

Hedge Funds Weigh In On Immatics

A number of large investors have recently modified their holdings of IMTX. T. Rowe Price Investment Management Inc. boosted its stake in shares of Immatics by 10.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock valued at $225,322,000 after buying an additional 2,075,987 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in Immatics by 43.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company’s stock valued at $278,000 after acquiring an additional 7,965 shares during the period. SummitTX Capital L.P. boosted its position in shares of Immatics by 117.7% during the 4th quarter. SummitTX Capital L.P. now owns 96,784 shares of the company’s stock worth $1,016,000 after purchasing an additional 52,318 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Immatics during the 4th quarter worth $575,000. Finally, Sphera Funds Management LTD. increased its holdings in shares of Immatics by 47.7% in the 4th quarter. Sphera Funds Management LTD. now owns 861,105 shares of the company’s stock valued at $9,042,000 after purchasing an additional 278,000 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Stock Down 1.6%

Shares of IMTX stock opened at $10.13 on Friday. The stock’s 50-day moving average price is $9.91 and its 200 day moving average price is $9.00. The stock has a market capitalization of $1.23 billion, a PE ratio of -9.93 and a beta of 1.36. Immatics has a 52-week low of $3.30 and a 52-week high of $12.41.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.